Strengths
- CB Insights lists Maven Clinic as a current unicorn at $1.70B.
- Company-owned sources substantiate the public product/category positioning.
- Public legal/privacy/security materials exist, but they are not substitutes for audit evidence.
Diligence report
Maven Clinic
Maven Clinic Public-Source Startup Diligence Report
The public record supports a scaled category participant in Virtual clinic and benefits platform for women and family health, fertility, maternity, pediatrics, menopause, and health-plan populations; diligence should focus on whether headline valuation is supported by durable revenue quality, retention, gross margin, defensible product differentiation, and manageable legal/regulatory exposure.
Company profile
Maven Clinic Public-Source Startup Diligence Report
Maven Clinic qualifies for a public-source diligence screen as a currently listed private unicorn with credible product and market evidence, but underwriting should remain gated on private financial, customer, legal, and security documents.
- Website
- www.mavenclinic.com
- Sector
- Virtual clinic and benefits platform for women and family health, fertility, maternity, pediatrics, menopause, and health-plan populations
- Geography
- United States headquartered with global employer and health-plan coverage
- Stage
- Late-stage private unicorn; Maven disclosed a $125M fundraise at a $1.7B valuation and CB Insights lists Maven at $1.70B
- Known aliases
- Maven, Maven Clinic Co., Maven Managed Benefit, MMB
- Report version
- 1.0
- Timezone
- UTC
Executive summary
Risks
- Public sources do not provide audited financials, revenue bridge, gross margin, burn, runway, AR aging, debt, or tax positions.
- Public scale/customer claims do not disclose ARR by customer, logo concentration, churn, expansion, renewal status, or reference quality.
- The target operates in a competitive category where incumbents and focused specialists can compete on bundle, price, distribution, or ecosystem.
- Public sources imply reliance on implementation, cloud, provider, partner, or technical ecosystems, but supplier concentration and contract terms are private.
Gaps
- Audited financial statements, revenue bridge, gross margin, cash, debt, AR aging, backlog, and plan-vs-actual data
- Fully diluted cap table, financing documents, option pool, liquidation preferences, notes/debt, and investor rights
- ARR by customer, top-20 contracts, renewal/churn/expansion cohorts, and customer references
- Sales productivity, CAC, channel attribution, quota attainment, implementation capacity, and pipeline conversion
- Roadmap, product analytics, technical architecture, IP/OSS scans, and release-quality metrics
Risk register
R-001: Limited public financial detail
Public sources do not provide audited financials, revenue bridge, gross margin, burn, runway, AR aging, debt, or tax positions.
Diligence request: Request audited financial statements, management accounts, KPI definitions, debt schedule, cash runway, tax/NOL analysis, and board plan-vs-actual packs.
R-002: Customer concentration and retention unknown
Public scale/customer claims do not disclose ARR by customer, logo concentration, churn, expansion, renewal status, or reference quality.
Diligence request: Request top-customer schedule, cohort retention, renewal pipeline, churned-customer interviews, and reference calls.
R-007: Security, privacy, and regulatory exposure
Public policies/certifications are useful but do not replace audit reports, incident logs, data-processing agreements, sector-specific compliance evidence, and legal/regulatory correspondence.
Diligence request: Request SOC/ISO reports, DPAs/BAAs where applicable, security questionnaire, incident log, regulator correspondence, and privacy impact assessments.
R-003: Competitive pressure and differentiation durability
The target operates in a competitive category where incumbents and focused specialists can compete on bundle, price, distribution, or ecosystem.
Diligence request: Request win/loss data, pipeline displacement reasons, pricing waterfall, and third-party customer references.
R-004: Partner, supplier, and ecosystem dependencies
Public sources imply reliance on implementation, cloud, provider, partner, or technical ecosystems, but supplier concentration and contract terms are private.
Diligence request: Request supplier spend, SLAs, termination rights, redundancy, subcontractor controls, and business-continuity plans.
R-005: Valuation and financing terms opacity
Public valuation anchors do not reveal liquidation preferences, secondary sales, debt, option pool, investor rights, or down-round protections.
Diligence request: Request fully diluted cap table, financing documents, investor rights agreements, debt schedule, and waterfall model.
R-006: Management depth and retention unknown
Public biographies do not provide full org chart, succession coverage, compensation, regretted attrition, or employee-relations issues.
Diligence request: Request org chart, leadership scorecards, attrition data, compensation bands, equity-refresh plan, and employee relations matters.
R-008: Product roadmap and ROI validation
Public product and roadmap claims require demos, adoption metrics, technical review, release evidence, and customer ROI validation.
Diligence request: Request product analytics, roadmap, release cadence, implementation KPIs, technical architecture, OSS/IP review, and customer ROI proof.
01Financial Information
Public sources verify Maven Clinic's unicorn valuation and financing/scale anchors, but financing terms remain private. Audited financial statements, revenue bridge, AR aging, backlog, and margin details were not public in reviewed sources.
I.D Other financial information
partially verified confidence: medium
Public sources verify Maven Clinic's unicorn valuation and financing/scale anchors, but financing terms remain private.
Evidence gaps
- Private company data-room materials were not available; request management-provided documents for this section.
Hidden risks
- Limited public financial detail
- Valuation and financing terms opacity
Follow-up questions
- Provide source documents, owner, and date for checklist items I.D.3.
| date | round | amount | post money | lead or participants | source |
|---|---|---|---|---|---|
| 2021-08 | Series D | $110M | $1B+ | not itemized in excerpt | SRC-007 |
| 2022-11 | Series E | $90M | $1.35B | General Catalyst led; CVS Health Ventures, La Famiglia, Intermountain Ventures participated | SRC-008 |
| 2024-10 | Series F / fundraise | $125M | $1.70B | not itemized in excerpt | SRC-002 |
| 2021-08-17 | CB Insights unicorn listing | not disclosed in CB row | $1.70B | Female Founders Fund, Oak HC/FT, Sequoia Capital listed by CB Insights | SRC-001 |
| stakeholder | public position | diligence caveat |
|---|---|---|
| Named investors | not itemized in excerpt; General Catalyst led; CVS Health Ventures, La Famiglia, Intermountain Ventures participated; not itemized in excerpt; Female Founders Fund, Oak HC/FT, Sequoia Capital listed by CB Insights | Request full cap table, option pool, liquidation preferences, SAFEs/notes, and secondary-sale details |
| Founders / employees | Not fully disclosed in reviewed public sources | Request founder ownership, employee option pool, vesting, and retention grants |
| Debt / off-balance-sheet liabilities | Not publicly disclosed | Request debt schedule, leases, customer prepayments, and any minimum commitments |
I.A Annual and quarterly financial information for the past three years
not publicly verifiable confidence: high
Audited financial statements, revenue bridge, AR aging, backlog, and margin details were not public in reviewed sources.
Evidence gaps
- Private company data-room materials were not available; request management-provided documents for this section.
Hidden risks
- Limited public financial detail
Follow-up questions
- Provide source documents, owner, and date for checklist items I.A.1, I.A.4, I.A.6.
| metric | public signal | evidence or request | verification status |
|---|---|---|---|
| Revenue / ARR | not publicly disclosed | Request audited financials, bookings, revenue by channel, and gross margin / care-cost bridge | not_publicly_verifiable |
| Covered lives | 28M lives supported worldwide | Company homepage claim | partially_verified |
| Employer customers | 2,300+ employers | Company homepage claim | partially_verified |
02Products
Public product pages support Maven Clinic's main product categories and platform positioning; profitability and adoption by module are private.
II.A Description of each product
partially verified confidence: medium
Public product pages support Maven Clinic's main product categories and platform positioning; profitability and adoption by module are private.
Evidence gaps
- Private company data-room materials were not available; request management-provided documents for this section.
Hidden risks
- Competitive pressure and differentiation durability
- Product roadmap and ROI validation
Follow-up questions
- Provide source documents, owner, and date for checklist items II.A.1, II.A.5, II.A.6.
| product | audience | key features | verification status |
|---|---|---|---|
| Fertility & Family Building | Employers, health plans, members trying to build families | Care navigation and benefit/payment administration including Maven Managed Benefit | verified |
| Maternity & Newborn Care | Pregnant members, postpartum families, Medicaid and commercial plans | Continuous care, risk support, mental health, doulas, newborn care | verified |
| Parenting & Pediatrics | Working parents and families | Virtual support across parenting, pediatrics, return to work | verified |
| Menopause & Midlife Health | Employees and health-plan members in midlife | Virtual care and specialized provider access | verified |
| Virtual Clinic | Members across 30+ specialties | On-demand virtual appointments across 30+ women’s and family health specialties | verified |
| offering | public pricing signal | diligence request | verification status |
|---|---|---|---|
| Target company pricing | Public pages emphasize demo/contact or solution-led sales rather than transparent rate cards | Request pricing book, discounting, ACV by segment, implementation fees, and renewal uplift | not_publicly_verifiable |
| Enterprise competitor pricing | Generally quote-based enterprise pricing in comparable markets | Benchmark discounts, multi-year commitments, and services attach | not_publicly_verifiable |
| ROI / value calculator or case-study claims | Public marketing materials emphasize ROI or outcomes | Validate with customer references, invoices, and realized KPI data | partially_verified |
03Customer Information
Public customer and scale signals exist for Maven Clinic, but customer concentration and renewal economics are not public. Public partner and ecosystem relationships are visible at a high level; contract economics are private. Top suppliers, cloud spend, provider dependency, and redundancy were not publicly verifiable.
III.A Top customers by application
partially verified confidence: medium
Public customer and scale signals exist for Maven Clinic, but customer concentration and renewal economics are not public.
Evidence gaps
- Private company data-room materials were not available; request management-provided documents for this section.
Hidden risks
- Customer concentration and retention unknown
Follow-up questions
- Provide source documents, owner, and date for checklist items III.A.
| customer or segment | source | use case | verification status |
|---|---|---|---|
| 2,300+ employers | Maven homepage | Employer customer scale claim | partially_verified |
| 28M lives worldwide | Maven homepage | Covered-life scale claim | partially_verified |
| Health plans / Medicaid | Maven health-plan page | Self-insured, fully-insured, and Medicaid populations; 10 Medicaid markets referenced | partially_verified |
| Top named customers | not listed in reviewed pages | Request contract list, ARR by customer, and cohort results | not_publicly_verifiable |
III.B Strategic relationships
partially verified confidence: medium
Public partner and ecosystem relationships are visible at a high level; contract economics are private.
Evidence gaps
- Private company data-room materials were not available; request management-provided documents for this section.
Hidden risks
- Partner, supplier, and ecosystem dependencies
Follow-up questions
- Provide source documents, owner, and date for checklist items III.B.
| partner | nature | public evidence or gap | verification status |
|---|---|---|---|
| Employers | B2B benefits distribution | Primary employer channel for family-health benefits | verified |
| Health plans | Payer distribution | Commercial and Medicaid health-plan programs | verified |
| Provider network / clinics | Clinical delivery dependency | Series F announcement references partnerships with clinics and in-person care | partially_verified |
| Benefits administrators / reimbursement platforms | Payment and benefits workflow | Maven Managed Benefit and reimbursement workflows referenced | partially_verified |
III.E Top suppliers
not publicly verifiable confidence: high
Top suppliers, cloud spend, provider dependency, and redundancy were not publicly verifiable.
Evidence gaps
- Private company data-room materials were not available; request management-provided documents for this section.
Hidden risks
- Partner, supplier, and ecosystem dependencies
Follow-up questions
- Provide source documents, owner, and date for checklist items III.E.
| supplier or dependency | role | public evidence | concentration risk |
|---|---|---|---|
| Cloud hosting / data infrastructure | Core service delivery | Provider, spend, redundancy, and exit plan not fully public | Potential concentration and margin risk; request architecture and contracts |
| Implementation / clinical / partner ecosystem | Customer delivery and support | Public partner/product materials indicate ecosystem dependencies but not economics | Request partner contracts, SLAs, and subcontractor controls |
| Security/compliance vendors | Enterprise trust and audit support | Privacy policy states PHI is regulated by HIPAA and employer/health-plan data is used for eligibility, benefits, reimbursement, and service improvement. | Request SOC reports, DPAs/BAAs where applicable, incident logs, and audit exceptions |
04Competition
Maven Clinic competes in a market with platform incumbents and focused specialists; public sources are enough for directional mapping but not win/loss proof.
IV.A Competitive landscape by market segment
partially verified confidence: medium
Maven Clinic competes in a market with platform incumbents and focused specialists; public sources are enough for directional mapping but not win/loss proof.
Evidence gaps
- Private company data-room materials were not available; request management-provided documents for this section.
Hidden risks
- Competitive pressure and differentiation durability
Follow-up questions
- Provide source documents, owner, and date for checklist items IV.A.1, IV.A.2.
| competitor | segment | product overlap | competitive intensity |
|---|---|---|---|
| Progyny | Fertility benefits and family-building benefits | Strong fertility-benefits competitor with public payer/provider network evidence | high |
| Carrot Fertility | Fertility and family-forming benefits | Direct employer benefit competition | high |
| Kindbody | Fertility clinics and benefits | Hybrid care-delivery and employer benefits overlap | medium |
| Included Health / health-plan point solutions | Virtual care/navigation | Competes for employer/health-plan benefits budget | medium |
| axis | target position | top competitor position | evidence or request |
|---|---|---|---|
| Product breadth | Public sources show broad platform positioning | Large incumbents may match modules or bundle adjacent workflows | Request win/loss data and third-party analyst/customer references |
| Pricing power | Not publicly verifiable | Competitors may discount, bundle, or use open-source economics | Request ACV trend, discount waterfall, and churn by competitor |
| Switching costs | Likely meaningful in regulated/enterprise workflows but not quantified | Incumbents may have stronger installed-base lock-in | Request implementation duration, migration costs, and renewal cohorts |
05Marketing, Sales, and Distribution
Public GTM signals show enterprise/partner/content motions for Maven Clinic; sales productivity and channel economics are private. Quota, compensation, sales-cycle, and pipeline conversion metrics were not public.
V.A Strategy and implementation
partially verified confidence: medium
Public GTM signals show enterprise/partner/content motions for Maven Clinic; sales productivity and channel economics are private.
Evidence gaps
- Private company data-room materials were not available; request management-provided documents for this section.
Hidden risks
- Customer concentration and retention unknown
- Partner, supplier, and ecosystem dependencies
Follow-up questions
- Provide source documents, owner, and date for checklist items V.A.1, V.A.2, V.A.4.
| channel | region or segment | public evidence | gap |
|---|---|---|---|
| Employer direct sales | Benefits and HR leaders | Employer page targets global workforces and demo motion | Request pipeline source, CAC, conversion, sales-cycle, and quota data |
| Health-plan partnerships | Commercial and Medicaid plans | Health-plan page describes outcomes-based care and Medicaid markets | Request pipeline source, CAC, conversion, sales-cycle, and quota data |
| Clinical/provider partnerships | In-person clinics and virtual providers | Series F roadmap describes clinic partnerships and virtual care model | Request pipeline source, CAC, conversion, sales-cycle, and quota data |
| signal | interpretation | diligence gap |
|---|---|---|
| Website CTAs / demo motion | Enterprise demand capture present | Suggests sales-led GTM; conversion and CAC are private |
| Customer stories or scale claims | Curated customer evidence available | Supports market credibility but may overrepresent best cases |
| Thought leadership / resources | Public resources indicate category education effort | Effectiveness and paid-vs-organic channel mix not public |
V.D Sales force productivity model
not publicly verifiable confidence: high
Quota, compensation, sales-cycle, and pipeline conversion metrics were not public.
Evidence gaps
- Private company data-room materials were not available; request management-provided documents for this section.
Hidden risks
- Limited public financial detail
- Customer concentration and retention unknown
Follow-up questions
- Provide source documents, owner, and date for checklist items V.D.1, V.D.2, V.D.3, V.D.4.
06Research and Development
Public sources identify selected leaders or R&D themes for Maven Clinic, but detailed budget, staffing, and roadmap governance are private. Public roadmap themes should be validated against release plans, adoption telemetry, security/IP review, and customer ROI.
VI.A Description of R&D organization
partially verified confidence: medium
Public sources identify selected leaders or R&D themes for Maven Clinic, but detailed budget, staffing, and roadmap governance are private.
Evidence gaps
- Private company data-room materials were not available; request management-provided documents for this section.
Hidden risks
- Management depth and retention unknown
- Product roadmap and ROI validation
Follow-up questions
- Provide source documents, owner, and date for checklist items VI.A.1, VI.A.2, VI.A.3.
| name or group | role | background or public signal |
|---|---|---|
| Kate Ryder | Founder and CEO | Public author of Series F strategy and roadmap |
| Clinical research / outcomes team | Peer-reviewed and claims-based studies | Series F page references 15 peer-reviewed studies and claims-based studies |
| Provider network operations | Virtual and in-person care partnerships | Series F page describes provider groups and clinic partnerships |
VI.B New Product Pipeline
partially verified confidence: medium
Public roadmap themes should be validated against release plans, adoption telemetry, security/IP review, and customer ROI.
Evidence gaps
- Private company data-room materials were not available; request management-provided documents for this section.
Hidden risks
- Product roadmap and ROI validation
Follow-up questions
- Provide source documents, owner, and date for checklist items VI.B.1, VI.B.3, VI.B.4.
| project | status | public signal or gap |
|---|---|---|
| Maven Managed Benefit | Publicly discussed | Fertility benefits administration and payment methodology roadmap |
| Value-based maternity care | Publicly discussed | Roadmap toward full-risk/value-based maternity models |
| Global women’s and family-health platform | Publicly marketed | Expansion across fertility, maternity, pediatrics, menopause, and health-plan populations |
07Management and Personnel
Public leadership information gives a partial view of management depth. Current headcount, hiring plan, attrition, and compensation data are not fully public. Turnover and employee-relations data require HR and legal diligence.
VII.C Senior management biographies
partially verified confidence: medium
Public leadership information gives a partial view of management depth.
Evidence gaps
- Private company data-room materials were not available; request management-provided documents for this section.
Hidden risks
- Management depth and retention unknown
Follow-up questions
- Provide source documents, owner, and date for checklist items VII.C.
| name | role | tenure or background |
|---|---|---|
| Kate Ryder | Founder and CEO | Authored Series F announcement |
| Clinical leadership | not fully listed in reviewed pages | Request leadership roster, medical director credentials, and provider oversight docs |
| Board / investors | not fully disclosed in reviewed pages | CB Insights lists selected investors; full board/cap table needed |
VII.B Historical and projected headcount by function and location
not publicly verifiable confidence: high
Current headcount, hiring plan, attrition, and compensation data are not fully public.
Evidence gaps
- Private company data-room materials were not available; request management-provided documents for this section.
Hidden risks
- Management depth and retention unknown
Follow-up questions
- Provide source documents, owner, and date for checklist items VII.B.
| function or metric | public anchor | source or gap |
|---|---|---|
| Current headcount | — | Not publicly disclosed in reviewed sources |
| Provider specialties | 30 | Homepage claims 30+ provider specialties |
VII.G Personnel Turnover
not publicly verifiable confidence: high
Turnover and employee-relations data require HR and legal diligence.
Evidence gaps
- Private company data-room materials were not available; request management-provided documents for this section.
Hidden risks
- Management depth and retention unknown
Follow-up questions
- Provide source documents, owner, and date for checklist items VII.G.1, VII.G.2.
| person or group | event | diligence note |
|---|---|---|
| Leadership changes | Public announcements or biographies reviewed where available | Request two-year executive departures, regretted attrition, offer-acceptance, and engagement data |
| Employee relations issues | No comprehensive public employee-relations record reviewed | Run formal litigation, labor, and Glassdoor-style review analysis before investment committee |
08Legal and Related Matters
No formal docket search was performed; legal schedules and counsel letters are required. IP ownership, patent/trademark schedules, OSS/license exposure, and invention assignments are not fully public. Privacy policy states PHI is regulated by HIPAA and employer/health-plan data is used for eligibility, benefits, reimbursement, and service improvement. Material customer, partner, supplier, privacy, security, and insurance contracts are private diligence items.
VIII.A Pending lawsuits against the Company
inconclusive confidence: low
No formal docket search was performed; legal schedules and counsel letters are required.
Evidence gaps
- Private company data-room materials were not available; request management-provided documents for this section.
Hidden risks
- Security, privacy, and regulatory exposure
Follow-up questions
- Provide source documents, owner, and date for checklist items VIII.A.
| case |
|---|
| No material litigation identified in reviewed public company/source pages |
| Customer / employment / IP disputes |
VIII.D Material patents, copyrights, licenses, and trademarks
not publicly verifiable confidence: high
IP ownership, patent/trademark schedules, OSS/license exposure, and invention assignments are not fully public.
Evidence gaps
- Private company data-room materials were not available; request management-provided documents for this section.
Hidden risks
- Security, privacy, and regulatory exposure
- Product roadmap and ROI validation
Follow-up questions
- Provide source documents, owner, and date for checklist items VIII.D.
| asset |
|---|
| Brand and product names |
| Software, data, models, and platform code |
VIII.G Regulatory agency problems
partially verified confidence: medium
Privacy policy states PHI is regulated by HIPAA and employer/health-plan data is used for eligibility, benefits, reimbursement, and service improvement.
Evidence gaps
- Private company data-room materials were not available; request management-provided documents for this section.
Hidden risks
- Security, privacy, and regulatory exposure
Follow-up questions
- Provide source documents, owner, and date for checklist items VIII.G.
| agency or regime |
|---|
| Privacy / data-protection regimes |
| Sector-specific regulators |
VIII.F Material contracts
not publicly verifiable confidence: high
Material customer, partner, supplier, privacy, security, and insurance contracts are private diligence items.
Evidence gaps
- Private company data-room materials were not available; request management-provided documents for this section.
Hidden risks
- Partner, supplier, and ecosystem dependencies
- Security, privacy, and regulatory exposure
Follow-up questions
- Provide source documents, owner, and date for checklist items VIII.F.
| contract or exposure |
|---|
| Customer contracts |
| Partner/supplier contracts |
| Insurance coverage |
Evidence
| ID | Claim | Status | Sources |
|---|---|---|---|
| EC-001 | CB Insights lists Maven as a current unicorn with a $1.70B valuation. | verified high | SRC-001 |
| EC-002 | Maven publicly disclosed a $125M fundraise at a $1.7B valuation in its Series F announcement. | verified high | SRC-002 |
| EC-003 | Maven offers a virtual clinic and benefits platform across fertility, maternity/newborn care, parenting, pediatrics, menopause, and midlife health. | verified high | SRC-003SRC-004SRC-005 |
| EC-004 | Maven claims scale with 2,300+ employers and 28M lives supported worldwide. | partially verified medium | SRC-003 |
| EC-005 | Maven sells to employers and health plans, including Medicaid markets and covered-life programs. | verified medium | SRC-004SRC-005 |
| EC-006 | Kate Ryder is Maven Clinic founder and CEO and authored the Series F announcement. | verified high | SRC-002 |
| EC-007 | Maven’s privacy policy flags HIPAA-regulated PHI and employer/health-plan data flows. | verified medium | SRC-006 |
| EC-008 | Maven’s valuation increased from $1B+ Series D to $1.35B Series E and $1.7B Series F public disclosures. | verified high | SRC-007SRC-008SRC-002 |
| EC-009 | Maven revenue, gross margin, medical loss ratio exposure, churn, customer concentration, and cap table are not publicly verifiable. | not publicly verifiable high | SRC-001SRC-002SRC-003 |
| EC-010 | Maven reports clinical outcomes research and value-based care ambitions, including 15 peer-reviewed studies and claims-based studies. | partially verified medium | SRC-002 |
| ID | Publisher | Title | Accessed |
|---|---|---|---|
| SRC-001 | CB Insights | The Complete List Of Unicorn Companies | 2026-05-29 |
| SRC-002 | Maven Clinic | Maven: A ten-year roadmap in women’s and family health | 2026-05-29 |
| SRC-003 | Maven Clinic | Maven Clinic - The next generation of care for women and families | 2026-05-29 |
| SRC-004 | Maven Clinic | Maven for Employers | 2026-05-29 |
| SRC-005 | Maven Clinic | Maven For Health Plans | 2026-05-29 |
| SRC-006 | Maven Clinic | Maven Clinic Privacy Policy | 2026-05-29 |
| SRC-007 | Maven Clinic | Thinking Bigger | 2026-05-29 |
| SRC-008 | Maven Clinic | Maven’s Second Act | 2026-05-29 |
Disclaimer
This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.